CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
REVENUES:
Net product sales	$ 4,745,094	$ 5,526,883	$ 16,919,436	$ 11,516,325
License and royalty revenue	0	25,000	0	125,322
R&D, milestone and grant revenue	262,292	369,904	825,093	1,529,972
TOTAL REVENUES	5,007,386	5,921,787	17,744,529	13,171,619
Cost of product sales	3,278,471	3,251,054	10,112,127	6,524,266
GROSS MARGIN	1,728,915	2,670,733	7,632,402	6,647,353
OPERATING EXPENSES:
Research and development expenses	1,005,645	1,242,295	3,363,819	3,697,309
Selling, general and administrative expenses	1,208,383	949,237	3,521,552	2,412,867
Total Operating Expenses	2,214,028	2,191,532	6,885,371	6,110,176
INCOME (LOSS) FROM OPERATIONS	(485,113)	479,201	747,031	537,177
OTHER INCOME (EXPENSES):
Interest income	2,269	1,278	5,386	4,315
Interest expense	(2,815)	(4,874)	(7,573)	(13,345)
TOTAL INCOME (EXPENSES)	(546)	(3,596)	(2,187)	(9,030)
INCOME (LOSS) BEFORE INCOME TAXES	(485,659)	475,605	744,844	528,147
Income tax provision (benefit)	(193,310)	0	295,220	0
NET INCOME (LOSS)	$ (292,349)	$ 475,605	$ 449,624	$ 528,147
Basic earnings (loss) per share (in dollars per share)	$ (0.04)	$ 0.06	$ 0.06	$ 0.07
Diluted earnings (loss) per share (in dollars per share)	$ (0.04)	$ 0.06	$ 0.05	$ 0.06
Weighted average number of shares outstanding, basic (in shares)	8,001,472	7,913,081	7,974,447	7,860,904
Weighted average number of shares outstanding, diluted (in shares)	8,001,472	8,508,740	8,616,917	8,644,940